Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 NCT04452318

casirivimab/imdevimab (Ronapreve) (n=753) vs. placebo (n=752)

randomized controlled trial   some concerns about risk of bias

Studied treatment

REGEN-COV (casirivimab 600mg plus imdevimab 600mg)
Single dose of REGEN-COV 1200 mg at day 1 via subcutaneous injection.

Control treatment

Placebo
Placebo at day 1 via subcutaneous injection.

Patients

COVID-19 prophylaxis (excluding children)

Method

Double-blind.

112 sites in the US, Romania and Moldova.

The trial consists of a 1-day screening/baseline period, a 28-day efficacy assessment period (EAP), and a 7-month follow-up period.

Remark

*Warning! The spread of new Sars-Cov2 variants is constantly evolving, this study was performed in a different viral context than today, its results should be interpreted accordingly.*